Lexaria Bioscience (LEXX) Enterprise Value (2010 - 2026)
Lexaria Bioscience (LEXX) posted Enterprise Value of -$3.9 million for Q2 2026, up 29.91% sequentially from -$5.5 million in Q1 2026, and up 22.79% YoY from -$3.2 million in Q2 2025.
Lexaria Bioscience (LEXX) Enterprise Value (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Enterprise Value for 17 years, with the latest figure at -$3.9 million in Q2 2026.
- Quarterly Enterprise Value rose 22.79% year-over-year to -$3.9 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$3.9 million (up 22.79% YoY) and the FY2025 annual result came in at -$2.2 million, up 67.85% from the prior year.
- Enterprise Value improved to -$3.9 million in Q2 2026 per LEXX's latest filing, from -$5.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.8 million in Q3 2023 and troughed at -$9.1 million in Q1 2022.
- A 5-year average of -$5.4 million and a median of -$5.1 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 71.56% in 2023, then sank 273.4% in 2024.
- Over 5 years, Enterprise Value stood at -$5.1 million in 2022, then jumped by 53.31% to -$2.4 million in 2023, then plunged by 254.64% to -$8.5 million in 2024, then surged by 43.35% to -$4.8 million in 2025, then increased by 19.63% to -$3.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$3.9 million, -$5.5 million, and -$4.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 2.12 Bn |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | -4.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -3.87 Mn |
| Feb 28, 2026 | -5.52 Mn |
| Nov 30, 2025 | -4.81 Mn |
| Aug 31, 2025 | -2.21 Mn |
| May 31, 2025 | -5.01 Mn |
| Feb 28, 2025 | -6.93 Mn |
| Nov 30, 2024 | -8.50 Mn |
| Aug 31, 2024 | -6.88 Mn |
| May 31, 2024 | -8.88 Mn |
| Feb 29, 2024 | -5.17 Mn |
| Nov 30, 2023 | -2.40 Mn |
| Aug 31, 2023 | -1.84 Mn |
| May 31, 2023 | -3.79 Mn |
| Feb 28, 2023 | -3.88 Mn |
| Nov 30, 2022 | -5.13 Mn |
| Aug 31, 2022 | -6.48 Mn |
| May 31, 2022 | -7.61 Mn |
| Feb 28, 2022 | -9.15 Mn |
| Nov 30, 2021 | -11.61 Mn |
| Aug 31, 2021 | -11.95 Mn |